

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Secukinumab for treating moderate to severe plaque psoriasis in children and young people ID1669

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (secukinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • British Skin Foundation • Changing Faces • Muslim Council of Britain • Psoriasis Association • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Society for Cutaneous Allergy • British Society for Rheumatology • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Canterbury and Coastal CCG • NHS England • NHS Isle of Wight CCG • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie Ltd (adalimumab) • Almirall Limited (dimethyl fumarate, tildrakizumab) • Amgen Ltd (adalimumab) • Biogen Biosimilars (adalimumab, etanercept, infliximab) • Biogen Idec Ltd (dimethyl fumarate) • Celgene Ltd (apremilast) • Eli Lilly and Company Limited (ixekizumab) • Janssen-Cilag Ltd (guselkumab, ustekinumab) • Leo Laboratories Limited (brodalumab) • Merck Sharp & Dohme Limited (infliximab)

Provisional stakeholder list for the technology appraisal of secukinumab for treating moderate to severe plaque psoriasis in children and young people ID1669. Issue date: November 2019

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Mylan (adalimumab) • Napp Pharmaceuticals Limited (infliximab) • Pfizer Limited (etanercept, infliximab) • Sandoz limited (adalimumab, etanercept, infliximab) • UCB Pharma Limited (certolizumab pegol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Skin Treatment & Research Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.